


PHARMACEUTICAL 2023

Xencor Inc Rank 43 of 446









PHARMACEUTICAL 2023



Xencor Inc Rank 43 of 446



The relative strengths and weaknesses of Xencor Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Xencor Inc compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 54% points. The greatest weakness of Xencor Inc is the variable Intangible Assets, reducing the Economic Capital Ratio by 2.3% points.

The company's Economic Capital Ratio, given in the ranking table, is 247%, being 204% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	675,342
Cost of Goods Sold	0
Intangible Assets	18,500
Liabilities, Current	63,844
Liabilities, Non-Current	54,926
Other Assets	93,241
Other Compr. Net Income	-5,442
Other Expenses	673
Other Liabilities	0
Other Net Income	27,965
Other Revenues	164,579
Property and Equipment	59,183
Research and Development	199,563
Selling, General and Administrative Expense	47,489

Output Variable	Value in 1000 USD
Assets	846,266
Liabilities	118,770
Expenses	247,725
Revenues	164,579
Stockholders Equity	727,496
Net Income	-55,181
Comprehensive Net Income	-57,902
Economic Capital Ratio	247%

